Canada markets closed

Curative Biotechnology, Inc. (CUBT)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0279+0.0024 (+9.63%)
At close: 01:42PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.0255
Open0.0254
BidN/A x N/A
AskN/A x N/A
Day's Range0.0254 - 0.0279
52 Week Range0.0051 - 0.0400
Volume10,700
Avg. Volume216,203
Market Cap17.159M
Beta (5Y Monthly)224.59
PE Ratio (TTM)N/A
EPS (TTM)-0.0100
Earnings DateApr 24, 2024 - Apr 27, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Curative Biotechnology, Inc. Announces Nomination of Dr. Theresa Heah to Board of Directors

    Palm Beach Gardens, FL, and Tokyo, Japan, March 31, 2024 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced the nomination to its Board of Directors of Dr. Theresa Heah. Dr. Heah is expected to join its Board of Directors immediately as an independent director. In addition to other Board duties Dr. Heah will serve on the newly created Cl

  • GlobeNewswire

    Curative Biotechnology, Inc. Announces Nomination of Dr. Jeffrey Liebmann to Board of Directors

    Appointment of Independent Director to become effective upon approval by and listing of common stock on a National Exchange Boca Raton, FL, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments for degenerative eye diseases today announced its nomination to its Board of Directors of Dr. Jeffrey Liebmann. Dr. Liebmann is expected to join its Board of Directors as an indepe

  • GlobeNewswire

    Curative Biotechnology Announces Establishment of Japanese Subsidiary for Licensing Transactions and Asset Acquisitions

    Appoints Paul Michaels Co-CEO of Parent and CEO of Subsidiary Boca Raton, FL, June 06, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel therapies for rare diseases and conditions, today announced that the registration process has begun for the creation of a subsidiary in Japan with an official incorporation date expected August 1, 2023, to facilitate licensing transactions and asset lic